Switching immunosuppressants to treat CMV after organ transplant
Part of Infections clinical trials.
This trial tests whether switching one of your anti-rejection medicines to a drug called everolimus can help clear a CMV infection. The goal is to see if this approach works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have received a solid organ transplant (kidney, liver, heart, lung, or pancreas).
- You have a CMV infection confirmed by a blood test.
- You are currently taking tacrolimus and MPA (with or without steroids) to prevent rejection.
- You have not received more than 72 hours of antiviral treatment for this CMV infection.
- You are not allergic to everolimus or similar medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
This study looks at how tacrolimus (a rejection-preventing medicine) should be dosed in the first days to years after a kidney transplant. It may help personalize dosing by comparing different patient groups, including using genetic testing.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This study compares two ways to prevent cytomegalovirus (CMV) infection after a kidney transplant in people who are at higher risk. One group gets a medicine called tacrolimus plus an MTOR inhibitor (sirolimus or everolimus) and only takes an antiviral if CMV is detected early. The other group gets tacrolimus plus mycophenolic acid and takes an antiviral medicine every day as a precaution. The goal is to find out which approach works better and is safer.
This study tests whether adding the drug everolimus can safely reduce the amount of tacrolimus (an anti-rejection medicine) needed after a first liver transplant. This may help protect your kidneys while still preventing organ rejection.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.